AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04056299 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: AR201 powder
Description: AR201 powder (Hen Egg allergen formulation) provided in capsules
Study NCT04056299 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo powder
Description: Placebo powder provided in capsules
Study NCT03207529 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alpelisib
Description: Given PO
Study NCT03207529 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzalutamide
Description: Given PO
Study NCT00645398 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin
Description: Pregabalin 225 mg BID taken orally, 2 capsules BID for 13 weeks (1 week titration phase + 12 weeks fixed-dose phase).
Study NCT00645398 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin
Description: Pregabalin 150 mg BID taken orally, 2 capsules BID for 13 weeks (1 week titration phase + 12 weeks fixed-dose phase).
Study NCT00645398 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin
Description: Pregabalin 300 mg BID taken orally, 2 capsules BID for 13 weeks (1 week titration phase + 12 weeks fixed-dose phase).
Study NCT00645398 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo capsules taken orally, 2 capsules BID for 13 weeks (1 week titration phase + 12 weeks fixed-dose phase).
Study NCT05229679 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: HPV testing
Description: All women age 23-29 resident in the pilot counties will be invited to HPV screening as of the study start date. The same invitation as currently used for women aged 30 and upwards will be used. This information clearly states that it is possible to opt out of the program and that data from the screening program will be collected to regional and national quality registers who will systematically evaluate the quality of the care. At the screening station, the samples are collected identically regardless of primary screening test used - there is no change in the procedures used neither for the woman or for the midwives taking the sample. HPV testing will be performed using the same purchased, CE-marked and accredited HPV screening platforms as currently used for women aged 30 and upwards. The cytology is according to the liquid-based cytology method.
Study NCT03328897 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omalizumab
Description: injection of 150mg or 300 mg
Study NCT03328897 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Injection of placebo
Study NCT02256501 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mono Nuclear Cell (MNC) transplantation
Description: Intracoronary administration of autologous bone marrow derived mononuclear cells
Study NCT05413187 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Medical Grade Cannabis oil
Description: MGC, 30% CBD and 1.5% Δ9-THC
Study NCT01372254 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Treatment
Description: Participants will receive a standard smoking cessation treatment in individual format. Treatment will be delivered in five, 90-minute individual sessions, and with two booster sessions assessed scheduled 2 and 4 weeks post quit. Participants will also receive 8 weeks of the transdermal nicotine patch.
Study NCT01372254 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BAD-AS
Description: The Behavioral Activation for Drug Abusing Smokers (BA-DAS) treatment protocol will incorporate elements of the ST along with behavioral activation strategies, modified for smoking. Treatment will consist of five, 90-minute individual sessions, and with two booster sessions scheduled 2 and 4 weeks post quit. Participants will also receive 8 weeks of the transdermal nicotine patch.
Study NCT01372254 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Transdermal Nicotine Patch
Description: 8 weeks of the Transdermal Nicotine Patch Nicoderm CQ at 24 hour doses of 21, 14, and 7 mg respectively depending on participant's initial level of nicotine use. Nicotine patch dose will decrease at 2 or 4 week increments also specific to the participant's initial nicotine level. Participants in both intervention arms will receive transdermal nicotine patch.
Study NCT01730989 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Estromineral
Study NCT04217096 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel liposome
Description: Patients receive paclitaxel liposome 175 mg/m\^2 (iv, 3h) on day 1 for 3 weeks. Treatment repeats every 3 weeks until the disease recurrence or unacceptable toxicity，death or begin a novel therapeutic
Study NCT04217096 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-1
Description: Patients receive S-1 at a dose according to the body surface area（\<1.25m\^2，40mg Bid；1.25\~1.5m\^2,50mg Bid；>1.50m\^2,60mg Bid）on days 1-14 for 3 weeks. Treatment repeats every 3 weeks until the disease recurrence or unacceptable toxicity，death or begin a novel therapeutic.
Study NCT01022476 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Raltegravir potassium
Description: one pill of raltegravir 400 mg twice a day
Study NCT01595880 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemigliptin and metformin HCl extended release
Description: Coadministration of gemigliptin 50mg and metformin HCl extended release 500mg, for 1 day
Study NCT01595880 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemigliptin/metformin HCl extended release
Description: Administration of combination of gemigliptin 50mg/metformin HCl extended release 500mg, for 1day.
Study NCT04004442 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: Avelumab: 800 mg IV every two weeks (on days 1 and 15 of a 28-day cycle)
Study NCT04004442 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AVB-S6-500
Description: AVB-S6-500: 10mg/kg IV every 2 weeks (on days 1 and 15 of a 28-day cycle) Potential dose reduction: AVB-S6-500: 5mg/kg IV weekly (on days 1, 8, 15 and 22 of a 28-day cycle)
Study NCT02179762 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: moderate exercise intervention
Description: Perform moderate exercise therapy
Study NCT02179762 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: vigorous exercise intervention - standard
Description: Perform HIIT exercise therapy on a standard stationary bike
Study NCT02179762 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: questionnaire administration
Description: Ancillary studies: Functional Assessment of Cancer Therapy-General (FACT-G), Godin Leisure-Time Exercise questionnaire, 24-hour diet recalls, USDA 5 Step Multiple Pass Method, Memorial Anxiety Scale for Prostate Cancer, Pittsburgh Sleep Quality Index (PSQI)
Study NCT02179762 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT01372254 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Transdermal Nicotine Patch
Description: 8 weeks of the Transdermal Nicotine Patch Nicoderm CQ at 24 hour doses of 21, 14, and 7 mg respectively depending on participant's initial level of nicotine use. Nicotine patch dose will decrease at 2 or 4 week increments also specific to the participant's initial nicotine level. Participants in both intervention arms will receive transdermal nicotine patch.
Study NCT00068406 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 3-Dimensional Conformal Radiation Therapy
Study NCT00068406 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Given IV
Study NCT00068406 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Conventional Surgery
Study NCT02319954 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Direct compression
Description: Direct compression by the surgeon with their hands on the nasal sidewall
Study NCT02997969 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: DNA-HIV-PT123 vaccine
Description: Contains a mixture of 3 DNA plasmids in a 1:1:1 ratio, each at 1.33 mg: 1) clade C ZM96 gag, 2) clade C ZM96 gp140, and 3) clade C CN54 pol-nef, delivered at a total dose 4 mg administered as 1 mL intramuscularly (IM)
Study NCT02997969 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Protein/MF59 vaccine
Description: clade C TV1.C gp120 Env and clade C 1086.C gp120 Env, each at a dose of 100 mcg, mixed with MF59 adjuvant, administered as 0.5 mL IM
Study NCT02997969 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Sodium Chloride, 0.9%, administered by IM injection at volumes to match the active products
Study NCT02997969 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sodium Chloride, 0.9%, administered by IM injection at volumes to match the active products
Study NCT03690726 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: repetitive transcranial magnetic stimulation
Description: Repetitive transcranial magnetic stimulation of the leg motor cortex, in combination with resistance training
Study NCT03690726 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham stimulation
Description: Imitated magnetic stimulation: An active coil will be activated under the subject's head, firing down into the mattress, while an inactive coil will be held over the scalp
Study NCT04959565 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nutritional behavioral intervention
Description: The participants will get access to an online platform where the FUEL recovery program will be initiated with session 1 immediately after baseline testing and the athletes are requested to follow the lectures lead by highly experienced sports dietitians for the respective weeks. Every other week for 16 weeks (8 sessions in total) participants will be offered individual nutrition counselling (one intervention group) by highly experienced sports nutritionists in each country, based on Motivational Interviewing, the individual's environmental and biological prerequisites, and the Transtheoretical Model, focusing on the individual's readiness to act on a new healthier behavior
Study NCT04959565 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nutritional behavioral intervention
Description: The participants will get access to an online platform where the FUEL recovery program will be initiated with session 1 immediately after baseline testing and the athletes are requested to follow the lectures lead by highly experienced sports dietitians for the respective weeks.
Study NCT01098383 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetyl-Choline Esterase Inhibitors and Choline supplements
Description: Donepezil will be used at initial dose of 2.5 mg/day (during the first two weeks), and an increased dose of 5 mg/day (from the 3rd week and on), according to the treatment protocol listed below. The tablets will be taken during breakfast.~AChE inhibitors are considered as potent agents for clinical use in Alzheimer's and Parkinson's dementias (Wevers \& Schroder, 1999) and treatment with these agents was proven to be well-tolerated, safe and effective in these populations. Cholinergic side effects are generally transient, mild and dose-related, and primarily include diarrhea, nausea, and vomiting.~Choline tablets will be taken at daily doses of 250 mg (in children with up to 40 kg body weight) and 500 mg (in children with more than 40 kg body weight), based on half of the adult daily dose.
Study NCT01098383 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Indistinguishable placebo tablets, matching both donepezil and choline
Description: Indistinguishable placebo tablets, matching both donepezil and choline, will be given in the same amounts and schedules
Study NCT06271135 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CAPILLARY REPAIR SERUM 30ml
Description: Cosmetic procedures were performed on a group of patients after a cosmetic interview containing questions about contraindications to the procedure. The treatment was performed 3-times at 2-week intervals and consisted of cavitation peeling and sonophore-sis with an antioxidant preparation dedicated to vascular skin. The F-808 Skin Scrubber device was used for the treatment. After a month, the procedure was repeated. The stages of a cosmetologist's procedure during a cosmetic intervention were as follows: 1. make-up removal; 2. skin diagnostics, exclusion of contraindications, discussion of the procedure; 3. cavitation peeling - gentle skin cleansing using ultrasound; 4. applying an antioxidant cosmetic mixture (composition: rutin, horse chestnut and arnica extract, acerola, vitamin C, moisturizing complex of algae); 5. performing sonophoresis treatment; 6. applying the cream at the end; 7. discussion of indications for further care.
Study NCT05640375 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Description: Single dose, 1 mg/kg
Study NCT00902252 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Usual
Description: All subjects will wear their usual pouching system for the first 21 days of the study.
Study NCT00902252 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Natura®
Description: All subjects will wear the Natura® Flexible Skin Barrier with Flange (Stomahesive® or Durahesive®) in the US and Natura® Stomahesive® Flexible Skin Barrier with Flange in Europe for 14 days.
Study NCT00902252 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vitala™
Description: After the successful completion of Stages 1 and 2, subjects will enter the ramp up schedule to allow the subject to adjust to the device. This consists of weekly increases in wear time of the Vitala™ device beginning with 4 hours of daily wear per week (Days 36 to 42), followed by 6 hours of daily wear time per week (Day 43 to 49), followed by 8 hours of daily wear time (Days 50 to 56) and progressing to 12 hours of daily wear per week (Day 57 to 215).
Study NCT02851953 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Aqueduct-100
Study NCT00850005 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin
Description: 2 g/kg divided over five days
Study NCT00850005 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: Same volume as experimental arm
Study NCT01272739 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: IHBG-10
Description: 500 mg of IHBG-10 taken 15 minutes prior to the three main meals of the day
Study NCT01272739 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo taken 15 minutes prior to the three main meals of the day
Study NCT00646100 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: transcatheter arterial chemoembolization
Description: chemo-lipiodolization with EADM 50mg, Lobaplatin 50mg, and MMC 6mg,plus particleembolization.
Study NCT01629693 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lotrafilcon B contact lenses
Description: Silicone hydrogel contact lenses (sphere or toric) per subject's habitual prescription
Study NCT01629693 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Comfilcon A contact lenses
Description: Silicone hydrogel contact lenses (sphere or toric) per subject's habitual prescription
Study NCT01259700 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High-risk patient standardized management package
Description: A primary-care based high cardiovascular risk management package delivered by village doctors
Study NCT01259700 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Community based salt reduction program
Description: A community-based salt reduction program delivered mainly by community health educators
Study NCT01189071 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Darifenacin
Description: an M3 selective anticholinergic medication. M3 muscarinic receptors are felt to be related to bladder and ureteral contractility. The ureteral and bladder spasms related to ureteral stents are felt to be due to inappropriate contractions. By using a selective M3 receptor, it is felt that there will be fewer side effects. Participants will be placed on the standard 15 mg oral daily dosage for 3 days prior to the stent being placed, day 3 being the am of the surgery.
Study NCT02987504 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Samalizumab
Description: Samalizumab is a humanized, anti CD200 monoclonal antibody provided as a sterile 5 mg/milliliters (mL) solution for IV administration.
Study NCT00415311 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Intravenous Recombinant Human Mannose-Binding Lectin (rhMBL)
Description: Intravenous(i.v.) administration for 8 weeks. Patients will be randomized to one of three cohorts: 0 mg/kg; 0.5 mg/kg, or 1.0 mg.kg
Study NCT01925807 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group Intervention
Description: The intervention will consist of 6 psycho-educational group sessions for caregivers and 6 psycho-educational group sessions for adolescents. Adolescent and caregiver sessions will be held separately and will focus on different issues. For adolescents, the group sessions will focus on coping strategies and emotional regulation. For caregivers, the group sessions will be focused on attachment, family environment, and validation.
Study NCT02843347 — intervention group
Intervention type: PROCEDURE
Intervention: Blood draw
Description: Three tubes of blood (28.5 mL in total) will be obtained at the Baseline Visit. The sample will be stored for future research.
Study NCT03791619 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Higher Cylinder Toric IOL
Description: Symfony Toric models ZXT300 and ZXT375 IOL
Study NCT03791619 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Lower Cylinder Toric IOL
Description: Symfony Toric model ZXT150 IOL
Study NCT02046369 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lurasidone
Description: Lurasidone flexibly dosed 20-80 mg once daily
Study NCT02046369 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo Comparator once daily
Study NCT01529749 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EFV/FTC/TDF + Losartan
Description: EFV/FTC/TDF --> oral, 600/200/245 mg, od Losartan --> initial dose 50 mg/24h, in patients with good tolerance, dose will be increased to 100 mg/24H in week 12.
Study NCT01529749 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EFV/FTC/TDF
Description: 600/200/245 mg, od, oral
Study NCT01529749 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FTC/TDF + MK-0518
Description: FTC/TDF --> 200/245 mg, oral MK-0518 --> 400 mg, oral
Study NCT01529749 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FTC/TDF+MK-0518+Losartan
Description: FTC/TDF --> 200/245 mg, oral MK-0518 --> 400 mg, oral Losartan --> -> initial dose 50 mg/24h, in patients with good tolerance, dose will be increased to 100 mg/24n in week 12.
Study NCT01005680 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: 500 milligrams/square meter (mg/m²) administered intravenously on Day 1 of each 21-day cycle, for 6 cycles
Study NCT01005680 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: 1250 mg/m² administered intravenously on Day 1 and Day 8 of each 21-day cycle, for 6 cycles
Study NCT01005680 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: 75 mg/m² administered intravenously on day 1 of each 21 day cycle, for 6 cycles
Study NCT01005680 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 75 mg/m² administered intravenously on day 1 of each 21 day cycle, for 6 cycles
Study NCT00583245 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gait Training
Description: Gait training with physical therapist 2/week for 3 months
Study NCT05734170 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Chia Seeds and instant oatmeal breakfast
Description: The final group was to consume one packet of instant oatmeal with two tablespoons of chia seeds mixed in with oatmeal for breakfast for 30 days.
Study NCT05734170 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Cheerio Breakfast
Description: Patients were instructed to consume one serving of Cheerios according to package instructions each morning for 30 days.
Study NCT05413187 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Olive oil and Chlorophyl
Study NCT03874000 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sintilimab
Description: Given IV
Study NCT05734170 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Instant Oatmeal breakfast
Description: The second group was assigned to consume one packet of instant oatmeal for 30 days.
Study NCT04768023 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Juvit D3
Description: Dosage based on the BMI as followed: for BMI under 25 - 4000 IU/day, for BMI between 25 and 30 - 5000 IU/day, and for BMI over 30 - 6000 IU/day.
Study NCT04768023 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching amount of vegetable oil to the vitamin D3.
Study NCT02684669 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naloxone
Description: active drug infusion
Study NCT02684669 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: placebo comparator